对肥胖相关糖尿病管理中的PPARγ抗剂进行分子对接分析
Aftab Ahmad1,1, Anwar A Alghamdi1,1
1Health Information Technology Department, The Applied College, King Abdulaziz University, Jeddah, Saudi Arabia.
Bioinformation
|October 27, 2023
概括
研究人员选了2320种化合物,以寻找针对PPARγ (氧酶增殖器激活受体玛) 的新型肥胖治疗方法. 四种化合物显示出强烈的结合亲和力,符合潜在药物开发的ADMET标准.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现
背景情况:
- 肥胖是一种全球代谢障碍,患病率越来越高.
- 过氧体增殖器激活受体玛 (PPARγ) 是代谢,胰岛素敏感性和脂肪生成的关键.
- PPARγ是肥胖和相关疾病的关键治疗标.
研究的目的:
- 识别具有强大的结合亲和力与PPARγ的新型化合物.
- 评估潜在的肥胖治疗候选药物.
主要方法:
- 在2320个生物活性化合物的选中,对PPARγ蛋白进行选.
- 结合亲和力的评估和常见氨基酸残留相互作用的识别.
- 对ADMET (吸收,分布,新陈代谢,分泌和毒性) 标准的评估.
主要成果:
- 四种化合物 (Z1982689600,Z2235802137,Z2235801970,Z2037275165) 呈现出高结合亲和度 (-12.1至-11.4千卡/mol),超过对照的亲和度 (-10.5千卡/mol).
- 这些化合物与PPARγ显著相互作用,与对照组共享常见残留物.
- 所有已识别的化合物都符合ADMET标准.
结论:
- 已识别的化合物显示出作为PPARγ抗剂的承诺,用于管理与肥胖相关的糖尿病.
- 进一步的研究是必要的,以优化化合物在实验室环境中的疗效.
相关概念视频
Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192
G Protein-coupled Receptors
12.2K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.2K
Transducer Mechanism: Nuclear Receptors
1.4K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
184
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
184


